On the 27th June 2018, Paula Sherriff MP introduced a 10-minute rule bill, supporting Changing Places, at the House of Commons. The bill asked for Changing Places Toilets to be made mandatory in all large new buildings.
“We’re fully behind this bill and the Changing Places Campaign”, says Nick Lang, UK Head of Marketing Teva OTC. “Sudocrem are proud to be at the forefront of activity to improve facilities for disabled children. Our award scheme recognises the people and places leading the way, but more needs to happen and that’s why this bill is so important”.
Read more about Sudocrem's Baby Changing Room Awards
Notes to Editors:
The National Childbirth Trust was established in 1956. It is a UK-based charity offering information and support in pregnancy, childbirth and early parenthood. It has worked with Sudocrem on the Baby Changing Room Awards for 3 years.
PAMIS (Promoting A More Inclusive Society) was established in 1992 and supports people with profound and multiple learning disabilities. Ten years ago, PAMIS cofounded the Changing Places Consortium and campaign to develop fully accessible toilets in the UK. A Changing Places toilet must be 12 square meters and have an adjustable bench, a tracking hoist, peninsula toilets and a stoma shelf.
For more information please contact:
Satellite PR: +44 (0) 1603 978030 Georgia@Satellitepr.com
About Teva UK Limited:
Teva UK Limited is one of the UK’s top ten pharmaceutical manufacturers, with a presence in the generics, over-the-counter, branded respiratory, central nervous system and hospitals markets. The company is part of Teva Pharmaceutical Industries Ltd. For more information, visit www.tevauk.com.
Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a leading global pharmaceutical company that delivers high-quality, patient-centric healthcare solutions used by millions of patients every day. Headquartered in Israel, Teva is the world’s largest generic medicines producer, leveraging its portfolio of more than 1,800 molecules to produce a wide range of generic products in nearly every therapeutic area. In specialty medicines, Teva has a world-leading position in innovative treatments for disorders of the central nervous system, including pain, as well as a strong portfolio of respiratory products. Teva integrates its generics and specialty capabilities in its global research and development division to create new ways of addressing unmet patient needs by combining drug development capabilities with devices, services and technologies. Teva's net revenues in 2017 were $22.4 billion. For more information, visit www.tevapharm.com.
Date of preparation: May 2018